[en] Despite its high prevalence and individual as well as
societal burden, migraine remains underdiagnosed and
undertreated. In recent years, the options for the management of
migraine patients have greatly expanded. A number of drugs
belonging to various pharmacological classes and deliverable by
several routes are now available both for the acute and the
preventive treatments of migraine. Nevertheless, disability and
satisfaction remain low in many subjects because treatments are
not accessible, not optimized, not effective, or simply not
tolerated. There is thus still considerable room for better
education, for more efficient therapies and for greater support
from national health systems. In spite of useful internationally
accepted guidelines, anti-migraine treatment has to be
individually tailored to each patient taking into account the
migraine subtype, the ensuing disability, the patient's previous
history and present expectations, and the co-morbid disorders.
In this article we will summarize the phen